New York-based health tech startup Bevel has secured $10 million in a Series A funding round led by prominent Silicon Valley venture firm General Catalyst to expand its AI-powered health companion app. This fresh capital injection will accelerate Bevel’s product development and broaden its user base, supporting its mission to help users make smarter, data-driven health decisions[7][1][3].
Bevel’s app unifies data from wearables, blood glucose monit...
Bevel’s app unifies data from wearables, blood glucose monitors, and other health sources to deliver actionable insights across key pillars of health: sleep, exercise, and nutrition. The company recently launched an innovative AI-powered nutrition tracking feature that integrates blood glucose data, offering users personalized nutrition scores for each meal. This allows individuals to understand in real time how their food choices impact glucose levels and overall wellbeing. The app also identifies patterns in users’ eating habits—such as late-night snacking or adherence to specific diets like keto—and connects these behaviors to other health metrics, providing tailored insights to optimize lifestyle choices[1][3].
Grey Nguyen, Bevel’s CEO and co-founder, emphasized that the...
Grey Nguyen, Bevel’s CEO and co-founder, emphasized that the new funding reflects investor confidence in a growing demand for proactive health solutions that extend beyond traditional care models. “Their support allows us to continue building tools that put individuals in control of their health decisions,” Nguyen said[1][3].
Ben Yang, Bevel’s Co-founder and CTO, highlighted the compan...
Ben Yang, Bevel’s Co-founder and CTO, highlighted the company’s overarching goal: “To help people connect the dots between their actions and their health outcomes,” underscoring the app’s role as a comprehensive health companion that empowers longevity and daily performance optimization[1].
General Catalyst, known for its strategic investments in tra...
General Catalyst, known for its strategic investments in transformative health technologies, continues to lead significant funding rounds in the digital health sector despite a broader slowdown in healthcare venture funding. The firm has invested heavily in healthcare startups focused on AI, software platforms, and life sciences innovation, deploying nearly $700 million across more than 30 life sciences companies since 2021. Their support of Bevel aligns with their focus on companies that harness AI and computational tools to address unmet medical needs and transform patient care[2][5][11].
Holly Maloney, Managing Director at General Catalyst, has no...
Holly Maloney, Managing Director at General Catalyst, has noted a maturing investment landscape in digital health, with a shift toward stable, long-term funding for companies delivering meaningful innovation. Bevel’s AI health companion exemplifies the type of strategic, high-quality startup General Catalyst is committed to backing as the sector evolves[4].
Founded in 2023, Bevel is part of a new wave of health techn...
Founded in 2023, Bevel is part of a new wave of health technology companies leveraging artificial intelligence to provide personalized, data-driven health insights. Its integration of blood glucose monitoring with nutrition tracking represents a significant advancement in proactive health management, enabling users to make informed decisions that impact their metabolic health and overall wellbeing[1][3].
The $10 million Series A funding from General Catalyst and S...
The $10 million Series A funding from General Catalyst and South Park Commons positions Bevel to scale its AI-driven platform and expand access to its proactive health solutions in the rapidly growing market for personalized digital health tools[1][3][7].
🔄 Updated: 10/30/2025, 4:20:08 PM
NEWS UPDATE: General Catalyst has led a $10 million Series A investment in Bevel, a New York–based AI health companion app that unifies data from wearables, nutrition apps, and daily habits into personalized health insights[1]. With this latest funding round announced on October 30, 2025, Bevel has now grown to over 100,000 daily active users—an eightfold increase in the past year—and boasts an 80% retention rate at 90 days, outpacing typical health app churn[1]. “Bevel’s mission to democratize health through intelligence and design deeply resonates with us,” said Neeraj Arora, General Catalyst managing director, emphasizing the app’s integration into users
🔄 Updated: 10/30/2025, 4:30:07 PM
In a significant development for global health technology, General Catalyst has invested $10 million in Bevel's AI health companion, marking a strategic move to enhance personalized wellness solutions. This investment is part of a broader trend where General Catalyst is actively supporting digital health startups, with a total of $490.2 million invested in Q1 2024 alone[2]. Bevel's innovative approach, which unifies data from wearables and daily habits, has garnered international attention for its potential to democratize health intelligence worldwide[1][3].
🔄 Updated: 10/30/2025, 4:40:08 PM
General Catalyst's $10 million Series A funding in Bevel marks a notable shift in the competitive digital health landscape, emphasizing long-term, high-engagement AI health tools rather than quick-hit fitness apps. Bevel’s rapid eightfold growth to over 100,000 daily active users with retention above 80% at 90 days reflects a strong market position amid fewer investor "tourists" in healthcare, as General Catalyst favors startups with durable, user-centered models for proactive health management[1][2]. This investment underscores a move towards AI-driven health companions that integrate wearables and biometric data to deliver personalized, actionable insights, differentiating Bevel from competitors focused on narrower health metrics or short-term goals[1][5].
🔄 Updated: 10/30/2025, 4:50:06 PM
In a recent development, General Catalyst's funding of Bevel's AI health tool highlights the growing interest in digital health technologies. While there is no specific regulatory or government response to this particular funding, the broader trend in AI health investments suggests a shift towards more strategic and long-term investments, as noted by Holly Maloney, managing director at General Catalyst[6]. As of now, regulatory bodies have not issued specific guidelines on AI health tools like Bevel, but policymakers are increasingly focusing on how to regulate AI in healthcare, ensuring safety and efficacy[14].
🔄 Updated: 10/30/2025, 5:00:07 PM
General Catalyst has recently funded Bevel, an AI health tool company, continuing its strong focus on computationally-enabled drug discovery and healthcare innovation. While specific round size details for Bevel's funding have not been disclosed, General Catalyst has deployed approximately $700 million in life sciences investments since 2021, emphasizing long-term patient capital and transformative AI-driven healthcare solutions[1][7]. This aligns with General Catalyst’s broader strategy to back pioneering AI health startups amid a stable and strategic digital health investment climate[4].
🔄 Updated: 10/30/2025, 5:10:06 PM
**Breaking News Update**: General Catalyst's investment in Bevel highlights the growing interest in AI-driven health solutions. Bevel's AI health companion, which unifies data from wearables and daily habits, has shown impressive user engagement, with over 100,000 daily active users and an 80% retention rate at 90 days[1]. Co-founder Grey Nguyen emphasizes the platform's ability to help users make continuous health improvements, stating, "Bevel meets you where you are, learns from your habits, and helps you make small changes that compound over time"[1].
🔄 Updated: 10/30/2025, 5:20:14 PM
General Catalyst has invested $10 million in Bevel’s Series A funding round to advance its AI-powered health companion app, which integrates data from wearables and blood glucose monitors to provide personalized, actionable insights across sleep, fitness, and nutrition[1][3][5]. Bevel’s AI leverages a proprietary database of over five million food items to deliver real-time nutrition scoring and identify behavioral patterns, enabling users to understand how lifestyle choices impact broader health metrics like sleep and glucose levels[5]. This investment comes amid Bevel’s rapid growth to over 100,000 daily active users with high engagement metrics—eight daily app opens and over 80% retention at 90 days—positioning the company to scale horizontally through expanded services and partnerships in
🔄 Updated: 10/30/2025, 5:30:13 PM
In the wake of General Catalyst's $10 million funding for Bevel's AI health companion, public reaction has been overwhelmingly positive, with users praising the app's ability to unify data from wearables and daily habits into personalized health insights. Bevel reports that it has grown more than eightfold in the past year, reaching over 100,000 daily active users, indicating strong consumer interest in proactive health management solutions[2]. "We're excited to support this team as they build the future of personal health," said Neeraj Arora, managing director at General Catalyst, highlighting the firm's confidence in Bevel's mission[2].
🔄 Updated: 10/30/2025, 5:40:12 PM
In the aftermath of General Catalyst's $10 million Series A investment in Bevel, a New York-based healthtech startup, the private equity market has shown significant interest in digital health innovations. However, specific stock price movements related to this investment are not publicly available since Bevel is not a publicly traded company. General Catalyst's commitment to Bevel reflects a broader trend of strategic investments in healthtech, underscoring the growing demand for AI-driven health solutions, as noted by General Catalyst's managing director, Neeraj Arora[1][4].
🔄 Updated: 10/30/2025, 5:50:13 PM
LIVE MARKET UPDATE: Following General Catalyst's $10 million Series A investment in Bevel's AI health companion on October 29, 2025[1][3], health tech sector analysts report heightened investor interest in AI-driven wellness startups, though Bevel remains privately held and no direct stock movement is observed. "Our investors recognize the growing demand for proactive health solutions that go beyond traditional care," said Bevel CEO Grey Nguyen, as the company accelerates product development with its latest nutrition and glucose tracking features[3].
🔄 Updated: 10/30/2025, 6:00:16 PM
General Catalyst’s $10 million investment in Bevel’s AI health companion comes amid ongoing federal regulatory uncertainty over AI in healthcare, with startups urging clearer government guidance to avoid overregulation that could stifle innovation. Industry voices warn that ambiguous oversight forces meticulous documentation and slower development, complicating efforts to keep pace with rapid tech advances in the $4 trillion U.S. health market[6]. No specific regulatory responses to Bevel itself have yet been disclosed.
🔄 Updated: 10/30/2025, 6:10:13 PM
**Breaking News Update**: While General Catalyst's funding of Bevel's AI health tool marks a significant investment in digital health, there is no specific regulatory or government response noted in the announcements. However, experts anticipate that as AI-driven health tools like Bevel's grow, they will face increased scrutiny from policymakers, who are actively exploring how to regulate AI in healthcare to ensure safety and efficacy[12]. In recent months, there has been a shift towards more strategic and long-term investment in digital health, which could influence future regulatory actions[6].
🔄 Updated: 10/30/2025, 6:20:15 PM
**Breaking News Update**: General Catalyst's recent investment in Bevel's AI health companion has sparked significant international interest, with the tool poised to integrate wearable data and daily habits to provide personalized health insights. Bevel's user base has grown over eightfold in the past year, reaching more than 100,000 daily active users, highlighting the global demand for such proactive health management solutions. As Neeraj Arora, managing director at General Catalyst, noted, "Bevel's mission to democratize health through intelligence and design deeply resonates with us," underscoring the global potential of this technology[4][2].
🔄 Updated: 10/30/2025, 6:30:14 PM
Following General Catalyst’s $10 million Series A funding for Bevel’s AI health companion, market reaction has been cautiously optimistic, highlighting growing investor interest in healthtech innovation. Although Bevel is a private company, industry analysts note the broader sector’s positive momentum, with health AI startups’ valuations rising by an average of 15% over the past quarter, reflecting confidence in personalized wellness management solutions[3][1]. General Catalyst’s managing director Neeraj Arora emphasized Bevel’s strong user engagement and retention as a key driver, stating, “It’s become part of people’s daily lives — not just another app,” signaling potential for substantial market impact[3].
🔄 Updated: 10/30/2025, 6:40:16 PM
## Breaking Update: General Catalyst Backs Bevel’s AI Health Tool—Global Impact and International Response
New York–based healthtech startup Bevel has secured $10 million in Series A funding from General Catalyst on October 30, 2025, to scale its AI-powered health companion, which now integrates data from wearables, sleep, fitness, and—in a global first—blood glucose monitors for nutrition tracking[2][5]. The app has grown over eightfold in the past year, surpassing 100,000 daily active users in the U.S., with an average user opening the app eight times daily and 90-day retention above 80%—signaling strong engagement in a market notorious for short-term churn[2